Market Overview

Adam Feuerstein Does Not Think AMAG Pharma Will Be Sold Until After Phase 3 Data


Adam Feuerstein, Senior Biotech Columnist at, tweeted this morning that he believes AMAG Pharmaceuticals (NASDAQ: AMAG) will eventually be sold, but not before the release of its phase 3 data in a couple months.

AMAG Pharmaceuticals announced this morning that it has hired Jefferies & Company as a strategic advisor. Shares of AMAG Pharma are currently trading up over 4% .

Posted-In: News Movers & Shakers FDA M&A General


Related Articles (AMAG)

Get Benzinga's Newsletters